Introduction and Aims: The 2023 Focused Update of the 2021 ESC Heart Failure (HF) Guidelines recommends the rapid up-titration (RT) of guideline-directed medical therapy (GDMT) for all patients hospitalised for HF to improve prognosis in light of the STRONG-HF trial. However, the real-world feasibility of RT and the optimal selection of suitable patients may cause difficulties as the STRONG-HF trial applied strict randomisation criteria. We aimed to assess the proportion of hospitalised HF patients suitable for RT after discharge. Methods: The proportion of patients eligible for RT based on the basic inclusion and exclusion criteria of the STRONG-HF trial (systolic blood pressure [SBP] ≥100 mm Hg, heart rate [HR] ≥60 min−1, serum potassium ≤5 mmol/L, estimated glomerular filtration rate [eGFR] ≥30 mL/min/1.73 m2, discharge N-terminal pro-B type natriuretic peptide [NT-proBNP] >1,500 pg/mL) was assessed in a consecutive patient cohort at a tertiary referral centre between April 01, 2021, and December 31, 2023. Results: Data from 408 consecutive patients were analysed (male: 71%; age: 62 [51–72] years; left ventricular ejection fraction: 27 [20–35]%; HF with reduced ejection fraction: 82%; hypertension: 67%; diabetes: 36%; atrial fibrillation: 47%). 78% of the patients were suitable for RT based on the SBP criterion, 93% on HR, 89% on serum potassium, and 91% on eGFR values. Thus, 60% were eligible for RT using the combined assessment of these parameters. When including the NT-proBNP value as well (60%), 34% of the cohort were eligible for RT. Conclusions: Based on our study, the proportion of patients suitable for RT of GDMT ranged from 34% to 60% based on the basic eligibility indicators of the STRONG-HF trial. Our results highlight the strategic importance of careful selection of patients eligible for RT.

1.
Savarese
G
,
Becher
PM
,
Lund
LH
,
Seferovic
P
,
Rosano
GMC
,
Coats
AJS
.
Global burden of heart failure: a comprehensive and updated review of epidemiology
.
Cardiovasc Res
.
2023
;
118
(
17
):
3272
87
.
2.
Cotter
G
,
Davison
B
,
Cohen-Solal
A
,
Freund
Y
,
Mebazaa
A
.
Targeting the “vulnerable” period: first 3-6 months after an acute heart failure admission–the light gets brighter
.
Eur J Heart Fail
.
2023
;
25
(
1
):
30
4
.
3.
Muk
B
.
Practical implementation of the 2021 European Society of Cardiology Heart Failure Guidelines – focusing on the guideline-directed medical therapy for heart failure with reduced ejection fraction
.
Cardiol Hung
.
2023
;
53
(
4
):
351
9
.
4.
McDonagh
TA
,
Metra
M
,
Adamo
M
,
Gardner
RS
,
Baumbach
A
,
Bohm
M
, et al
.
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
.
Eur Heart J
.
2021
;
42
(
36
):
3599
726
.
5.
McDonagh
TA
,
Metra
M
,
Adamo
M
,
Gardner
RS
,
Baumbach
A
,
Böhm
M
, et al
.
2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
.
Eur Heart J
.
2023
;
44
(
37
):
3627
39
.
6.
Dunlay
SM
,
Killian
JM
,
Roger
VL
,
Schulte
PJ
,
Blecker
SB
,
Savitz
ST
, et al
.
Guideline-directed medical therapy in newly diagnosed heart failure with reduced ejection fraction in the community
.
J Card Fail
.
2022
;
28
(
10
):
1500
8
.
7.
Muk
B
,
Bánfi-Bacsárdi
F
,
Vámos
M
,
Pilecky
D
,
Majoros
Z
,
Török
GM
, et al
.
The impact of specialised heart failure outpatient care on the long-term application of guideline-directed medical therapy and on prognosis in heart failure with reduced ejection fraction
.
Diagnostics
.
2024
;
14
(
2
):
131
.
8.
Heidenreich
PA
,
Bozkurt
B
,
Aguilar
D
,
Allen
LA
,
Byun
JJ
,
Colvin
MM
, et al
.
2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American college of Cardiology/American heart association joint committee on clinical practice guidelines
.
Circulation
.
2022
;
145
(
18
):
e895
1032
.
9.
Shahid
I
,
Fonarow
GC
,
Greene
SJ
.
Time to quadruple guideline-directed medical therapy as a key performance measure for heart failure
.
J Card Fail
.
2023
;
29
(
5
):
730
3
.
10.
Cotter
G
,
Deniau
B
,
Davison
B
,
Edwards
C
,
Adamo
M
,
Arrigo
M
, et al
.
Optimization of evidence-based heart failure medications after an acute heart failure admission: a secondary analysis of the STRONG-HF randomized clinical trial
.
JAMA Cardiol
.
2024
;
9
(
2
):
114
24
.
11.
Mebazaa
A
,
Davison
B
,
Chioncel
O
,
Cohen-Solal
A
,
Diaz
R
,
Filippatos
G
, et al
.
Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial
.
Lancet
.
2022
;
400
(
10367
):
1938
52
.
12.
Kimmoun
A
,
Cotter
G
,
Davison
B
,
Takagi
K
,
Addad
F
,
Celutkiene
J
, et al
.
Safety, Tolerability and efficacy of Rapid Optimization, helped by NT-proBNP and GDF-15, of Heart Failure therapies (STRONG-HF): rationale and design for a multicentre, randomized, parallel-group study
.
Eur J Heart Fail
.
2019
;
21
(
11
):
1459
67
.
13.
Butler
J
,
Talha
KM
,
Fonarow
GC
.
STRONG-HF and implementing heart failure therapies: godspeed … with care
.
Circulation
.
2023
;
147
(
16
):
1189
91
.
14.
Rickham
PP
.
Human experimentation. Code of ethics of the world medical association. Declaration of Helsinki
.
Br Med J
.
1964
;
2
(
5402
):
177
.
15.
G-CHF Investigators
,
Joseph
P
,
Roy
A
,
Lonn
E
,
Störk
S
,
Floras
J
, et al
.
Global variations in heart failure etiology, management, and outcomes
.
JAMA
.
2023
;
329
(
19
):
1650
61
.
16.
Pierce
JB
,
Vaduganathan
M
,
Fonarow
GC
,
Ikeaba
U
,
Chiswell
K
,
Butler
J
, et al
.
Contemporary use of sodium-glucose cotransporter-2 inhibitor therapy among patients hospitalized for heart failure with reduced ejection fraction in the US: the Get with the guidelines-heart failure Registry
.
JAMA Cardiol
.
2023
;
8
(
7
):
652
61
.
17.
Greene
SJ
,
Ayodele
I
,
Pierce
JB
,
Khan
MS
,
Lewsey
SC
,
Yancy
CW
, et al
.
Eligibility and projected benefits of Rapid Initiation of quadruple therapy for newly diagnosed Heart Failure
.
JACC Heart Fail
.
2024
;
12
(
8
):
1365
77
.
18.
Tromp
J
,
Ouwerkerk
W
,
van Veldhuisen
DJ
,
Hillege
HL
,
Richards
AM
,
van der Meer
P
, et al
.
A systematic review and network meta-analysis of pharmacological treatment of heart failure with reduced ejection fraction
.
JACC Heart Fail
.
2022
;
10
(
2
):
73
84
.
19.
Banerjee
M
,
Pal
R
,
Nair
K
,
Mukhopadhyay
S
.
SGLT2 inhibitors and cardiovascular outcomes in heart failure with mildly reduced and preserved ejection fraction: a systematic review and meta-analysis
.
Indian Heart J
.
2023
;
75
(
2
):
122
7
.
20.
Blumer
V
,
Mentz
RJ
,
Sun
JL
,
Butler
J
,
Metra
M
,
Voors
AA
, et al
.
Prognostic role of prior heart failure hospitalization among patients hospitalized for worsening chronic heart failure
.
Circ Heart Fail
.
2021
;
14
(
4
):
e007871
.
21.
Bánfi-Bacsárdi
F
,
Muk
B
,
Pilecky
D
,
Duray
GZ
,
Kiss
RG
,
Nyolczas
N
.
The optimization of guideline-directed medical therapy during hospitalization among patients with heart failure with reduced ejection fraction in daily clinical practice
.
Cardiology
.
2023
;
148
(
1
):
27
37
.
22.
Muk
B
,
Pilecky
D
,
Bánfi-Bacsárdi
F
,
Füzesi
T
,
Gergely
GT
,
Komáromi
A
, et al
.
The changes in the pharmacotherapy of heart failure with reduced ejection fraction and its effect on prognosis: experience in the Hungarian clinical practice
.
Orv Hetil
.
2024
;
165
(
18
):
698
710
.
23.
Ohata
T
,
Niimi
N
,
Shiraishi
Y
,
Nakatsu
F
,
Umemura
I
,
Kohno
T
, et al
.
Initiation and up-titration of guideline-based medications in hospitalized acute heart failure patients: a report from the west Tokyo heart failure Registry
.
Circ J
.
2023
;
88
(
1
):
22
30
.
24.
Moghaddam
N
,
Hawkins
NM
,
McKelvie
R
,
Poon
S
,
Joncas
SX
,
MacFadyen
J
, et al
.
Patient eligibility for established and novel guideline-directed medical therapies after acute heart failure hospitalization
.
JACC Heart Fail
.
2023
;
11
(
5
):
596
606
.
25.
Greene
SJ
,
Fonarow
GC
,
Vaduganathan
M
,
Khan
SS
,
Butler
J
,
Gheorghiade
M
.
The vulnerable phase after hospitalization for heart failure
.
Nat Rev Cardiol
.
2015
;
12
(
4
):
220
9
.
26.
Gergely
GT
,
Bánfi-Bacsárdi
F
,
Komáromi
A
,
Pilecky
D
,
Boldizsár
EM
,
Flegler
D
, et al
.
Rapid up-titration of guide-directed medical therapy after a heart failure hospitalisation
.
Orv Hetil
.
2024
;
165
(
31
):
1197
205
.
27.
Greene
SJ
,
Khan
MS
,
Butler
J
.
Why do clinicians not prescribe quadruple medical therapy for heart failure with reduced ejection fraction
.
Eur J Heart Fail
.
2024
;
26
(
2
):
338
41
.
28.
Bánfi-Bacsárdi
F
,
Pilecky
D
,
Vámos
M
,
Majoros
Z
,
Török
GM
,
Borsányi
TD
, et al
.
The effect of kidney function on guideline-directed medical therapy implementation and prognosis in heart failure with reduced ejection fraction
.
Clin Cardiol
.
2024
;
47
(
2
):
e24244
.
29.
Bánfi-Bacsárdi
F
,
Boldizsár
EM
,
Gergely
GT
,
Forrai
Z
,
Kazay
Á
,
Füzesi
T
, et al
.
The role of complex patient education program in heart failure care
.
Orv Hetil
.
2024
;
165
(
37
):
1461
71
.
30.
D’Amario
D
,
Rodolico
D
,
Delvinioti
A
,
Laborante
R
,
Iacomini
C
,
Masciocchi
C
, et al
.
Eligibility for the 4 pharmacological pillars in heart failure with reduced ejection fraction at discharge
.
J Am Heart Assoc
.
2023
;
12
(
13
):
e029071
.
31.
Rao
VN
,
Murray
E
,
Butler
J
,
Cooper
LB
,
Cox
ZL
,
Fiuzat
M
, et al
.
In-hospital initiation of sodium-glucose cotransporter-2 inhibitors for heart failure with reduced ejection fraction
.
J Am Coll Cardiol
.
2021
;
78
(
20
):
2004
12
.
32.
Muk
B
,
Vámos
M
,
Bógyi
P
,
Szabó
B
,
Dékány
M
,
Vágány
D
, et al
.
The impact of serum concentration-guided digoxin therapy on mortality of heart failure patients: a long-term follow-up, propensity-matched cohort study
.
Clin Cardiol
.
2020
;
43
(
12
):
1641
8
.
33.
Lam
PH
,
Packer
M
,
Fonarow
GC
,
Faselis
C
,
Allman
RM
,
Morgan
CJ
, et al
.
Early effects of starting doses of enalapril in patients with chronic heart failure in the SOLVD treatment trial
.
Am J Med
.
2020
;
133
(
2
):
e25
31
.
34.
Pitt
B
,
Zannad
F
,
Remme
WJ
,
Cody
R
,
Castaigne
A
,
Perez
A
, et al
.
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators
.
N Engl J Med
.
1999
;
341
(
10
):
709
17
.
35.
Krum
H
,
Roecker
EB
,
Mohacsi
P
,
Rouleau
JL
,
Tendera
M
,
Coats
AJ
, et al
.
Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS Study
.
JAMA
.
2003
;
289
(
6
):
712
8
.
36.
McMurray
JJV
,
Solomon
SD
,
Inzucchi
SE
,
Køber
L
,
Kosiborod
MN
,
Martinez
FA
, et al
.
Dapagliflozin in patients with heart failure and reduced ejection fraction
.
N Engl J Med
.
2019
;
381
(
21
):
1995
2008
.
37.
Packer
M
,
Anker
SD
,
Butler
J
,
Filippatos
G
,
Pocock
SJ
,
Carson
P
, et al
.
Cardiovascular and renal outcomes with empagliflozin in heart failure
.
N Engl J Med
.
2020
;
383
(
15
):
1413
24
.
38.
Packer
M
,
Butler
J
,
Zannad
F
,
Filippatos
G
,
Ferreira
JP
,
Pocock
SJ
, et al
.
Effect of empagliflozin on worsening heart failure events in patients with heart failure and preserved ejection fraction: EMPEROR-preserved trial
.
Circulation
.
2021
;
144
(
16
):
1284
94
.
39.
Tomasoni
D
,
Davison
B
,
Adamo
M
,
Pagnesi
M
,
Mebazaa
A
,
Edwards
C
, et al
.
Safety indicators in patients receiving high-intensity care after hospital admission for acute heart failure: the STRONG-HF trial
.
J Card Fail
.
2024
;
30
(
4
):
525
37
.
40.
Rosano
GMC
,
Moura
B
,
Metra
M
,
Böhm
M
,
Bauersachs
J
,
Ben Gal
T
, et al
.
Patient profiling in heart failure for tailoring medical therapy. A consensus document of the Heart Failure Association of the European Society of Cardiology
.
Eur J Heart Fail
.
2021
;
23
(
6
):
872
81
.
41.
Komajda
M
,
Anker
SD
,
Cowie
MR
,
Filippatos
GS
,
Mengelle
B
,
Ponikowski
P
, et al
.
Physicians’ adherence to guideline-recommended medications in heart failure with reduced ejection fraction: data from the QUALIFY global survey
.
Eur J Heart Fail
.
2016
;
18
(
5
):
514
22
.
42.
Bánfi-Bacsárdi
F
,
Vámos
M
,
Majoros
Z
,
Török
G
,
Pilecky
D
,
Duray
GZ
, et al
.
The effect of kidney function on the optimization of medical therapy and on mortality in heart failure with reduced ejection fraction
.
Orv Hetil
.
2023
;
164
(
35
):
1387
96
.
43.
Meekers
E
,
Dhont
S
,
Mullens
W
.
Diuretic therapy in acute decompensated heart failure
.
Cardiol Hung
.
2024
;
54
(
3
):
193
9
.
44.
Vamos
M
,
Oldgren
J
,
Nam
GB
,
Lip
GYH
,
Calkins
H
,
Zhu
J
, et al
.
Dronedarone vs. placebo in patients with atrial fibrillation or atrial flutter across a range of renal function: a post hoc analysis of the ATHENA trial
.
Eur Heart J Cardiovasc Pharmacother
.
2022
;
8
(
4
):
363
71
.
45.
Bánfi-Bacsárdi
F
,
Ormos
F
,
Muk
B
.
The importance of chronic kidney disease in the management of patients with heart failure
.
Cardiol Hung
.
2024
;
54
(
3
):
206
11
.
46.
Cautela
J
,
Tartiere
JM
,
Cohen-Solal
A
,
Bellemain-Appaix
A
,
Theron
A
,
Tibi
T
, et al
.
Management of low blood pressure in ambulatory heart failure with reduced ejection fraction patients
.
Eur J Heart Fail
.
2020
;
22
(
8
):
1357
65
.
47.
Melendo-Viu
M
,
Dobarro
D
,
Marchán López
Á
,
Domínguez
LM
,
Raposeiras-Roubín
S
,
Abu-Assi
E
, et al
.
Hypotension at heart failure discharge: should it be a limiting factor for drug titration
.
Int J Cardiol
.
2023
;
386
:
59
64
.
48.
Bánfi-Bacsárdi
F
,
Muk
B
,
Majoros
ZS
,
Török
G
,
Pilecky
D
,
Duray
GZ
, et al
.
The effect of long-term application of guideline-directed medical therapy on systolic blood pressure in hospitalized patients with heart failure with reduced ejection fraction
.
Eur Heart J
.
2023
;
44
(
Supplement_2
).
49.
Girerd
N
,
Coiro
S
,
Benson
L
,
Savarese
G
,
Dahlström
U
,
Rossignol
P
, et al
.
Hypotension in heart failure is less harmful if associated with high or increasing doses of heart failure medication: insights from the Swedish Heart Failure Registry
.
Eur J Heart Fail
.
2024
;
26
(
2
):
359
69
.
50.
Ryan
DK
,
Banerjee
D
,
Jouhra
F
.
Management of heart failure in patients with chronic kidney disease
.
Eur Cardiol
.
2022
;
17
:
e17
.
51.
McAlister
FA
,
Ezekowitz
J
,
Tarantini
L
,
Squire
I
,
Komajda
M
,
Bayes-Genis
A
, et al
.
Renal dysfunction in patients with heart failure with preserved versus reduced ejection fraction: impact of the new Chronic Kidney Disease-Epidemiology Collaboration Group formula
.
Circ Heart Fail
.
2012
;
5
(
3
):
309
14
.
52.
Ter Maaten
JM
,
Mebazaa
A
,
Davison
B
,
Edwards
C
,
Adamo
M
,
Arrigo
M
, et al
.
Early changes in renal function during rapid up-titration of guideline-directed medical therapy following an admission for acute heart failure
.
Eur J Heart Fail
.
2023
;
25
(
12
):
2230
42
.
53.
Mullens
W
,
Martens
P
,
Testani
JM
,
Tang
WHW
,
Skouri
H
,
Verbrugge
FH
, et al
.
Renal effects of guideline-directed medical therapies in heart failure: a consensus document from the Heart Failure Association of the European Society of Cardiology
.
Eur J Heart Fail
.
2022
;
24
(
4
):
603
19
.
54.
Heerspink
HJL
,
Stefánsson
BV
,
Correa-Rotter
R
,
Chertow
GM
,
Greene
T
,
Hou
F-F
, et al
.
Dapagliflozin in patients with chronic kidney disease
.
N Engl J Med
.
2020
;
383
(
15
):
1436
46
.
55.
McMurray
JJ
,
Packer
M
,
Desai
AS
,
Gong
J
,
Lefkowitz
MP
,
Rizkala
AR
, et al
.
Angiotensin-neprilysin inhibition versus enalapril in heart failure
.
N Engl J Med
.
2014
;
371
(
11
):
993
1004
.
56.
Vardeny
O
,
Claggett
B
,
Anand
I
,
Rossignol
P
,
Desai
AS
,
Zannad
F
, et al
.
Incidence, predictors, and outcomes related to hypo- and hyperkalemia in patients with severe heart failure treated with a mineralocorticoid receptor antagonist
.
Circ Heart Fail
.
2014
;
7
(
4
):
573
9
.
57.
Pitt
B
,
Remme
W
,
Zannad
F
,
Neaton
J
,
Martinez
F
,
Roniker
B
, et al
.
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction
.
N Engl J Med
.
2003
;
348
(
14
):
1309
21
.
58.
Fuery
MA
,
Leifer
ES
,
Samsky
MD
,
Sen
S
,
O’Connor
CM
,
Fiuzat
M
, et al
.
Prognostic impact of repeated NT-proBNP measurements in patients with heart failure with reduced ejection fraction
.
JACC Heart Fail
.
2024
;
12
(
3
):
479
87
.
59.
Adamo
M
,
Pagnesi
M
,
Mebazaa
A
,
Davison
B
,
Edwards
C
,
Tomasoni
D
, et al
.
NT-proBNP and high intensity care for acute heart failure: the STRONG-HF trial
.
Eur Heart J
.
2023
;
44
(
31
):
2947
62
.
You do not currently have access to this content.